Hepatitis b breakthrough? new drug AHB-137 shows promise in Long-Term Follow-Up

NCT ID NCT07146100

Recruiting now Disease control Sponsor: Ausper Biopharma Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 30, 2026 · Updated 2 times

Summary

This study checks if people with chronic hepatitis B who got better with the drug AHB-137 stay virus-free over time. About 200 adults who already responded to AHB-137 will be followed for years. The goal is to see if the virus stays undetectable and if liver health improves without needing more treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic hepatitis B virus infection hepatitis B virus infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC HEPATITIS B

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

AusperBio Investigational Site
RECRUITING

Chongqing, Chongqing Municipality, China

Contact Email: •••••@•••••
AusperBio Investigational Site
RECRUITING

Fuzhou, Fujian, China

Contact Email: •••••@•••••
AusperBio Investigational Site
RECRUITING

Guangzhou, Guangdong, China
AusperBio Investigational Site
RECRUITING

Guangzhou, Guangdong, China

Contact Email: •••••@•••••

Contact Email: •••••@•••••
AusperBio Investigational Site
RECRUITING

Changhou, Jiangsu, China

Contact Email: •••••@•••••
AusperBio Investigational Site
RECRUITING

Zhenjiang, Jiangsu, China

Contact Email: •••••@•••••
AusperBio Investigational Site
RECRUITING

Changchun, Jilin, China

Contact Email: •••••@•••••
AusperBio Investigational Site
RECRUITING

Hangzhou, Zhejiang, China

Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.